ARDELYX, INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
ARDELYX, INC. (ARDX) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $811.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2023-03-02
- ARDELYX, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $811.00K.
- ARDELYX, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $0.00.
- ARDELYX, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2020 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2022-12-31 | $811.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |